Aitken M L, Tonelli M R
Division of Pulmonary and Critical Care Medicine, Department of Medicine, School of Medicine, University of Washington, Seattle 98195, USA.
Chest. 2000 Dec;118(6):1598-602. doi: 10.1378/chest.118.6.1598.
Patients with cystic fibrosis (CF) frequently require recurrent courses of IV antibiotics to treat acute exacerbations of their pulmonary disease. Over time, CF patients often lose peripheral access, and indwelling central venous catheters are placed. We attempted to determine the type and incidence of catheter complications so that CF patients could be fully informed of the risks prior to placement of these catheters.
The charts of all CF patients who attended the Adult Cystic Fibrosis Clinic of the University of Washington Medical Center from January 1989 through December 1998 were reviewed. Demographic information was obtained along with the type and duration of catheter, type and number of complications, and the use of anticoagulant medication.
Of the 218 CF patients who attended the clinic, 65 patients (30%) had indwelling catheters in place at some time during the study period. A total of 87 catheters were placed into these 65 patients. The total number of catheter-days for first indwelling catheters was 68,220. The total number of catheter-days for all catheters was 75,660 (210 catheter-years). Thirty-five catheter-related complications were identified, occurring in 26 patients. Complications included thrombosis (n = 14), infections (n = 9), mechanical problems (n = 6), pneumothorax (n = 3), superior vena cava syndrome/stenosis (n = 2), and air embolism (n = 1), for an overall complication rate of 0. 463/1,000 catheter-days.
We conclude that indwelling catheters are relatively safe in patients with CF. Good infection control policies appear to prevent most infectious complications. The most common complication is that of thrombosis, which may be recurrent in some patients. Consideration should be given to prophylactic warfarin therapy despite the potential risk of significant hemoptysis in this patient population.
囊性纤维化(CF)患者经常需要反复静脉使用抗生素来治疗肺部疾病的急性加重。随着时间的推移,CF患者常常失去外周静脉通路,需要放置中心静脉留置导管。我们试图确定导管并发症的类型和发生率,以便CF患者在放置这些导管之前能够充分了解风险。
回顾了1989年1月至1998年12月在华盛顿大学医学中心成人囊性纤维化诊所就诊的所有CF患者的病历。收集了人口统计学信息、导管类型和使用时间、并发症类型和数量以及抗凝药物的使用情况。
在就诊的218例CF患者中,65例(30%)在研究期间的某些时间放置了中心静脉留置导管。这65例患者共放置了87根导管。首次留置导管的总导管日数为68220天。所有导管的总导管日数为75660天(210导管年)。共发现35例与导管相关的并发症,发生在26例患者中。并发症包括血栓形成(n = 14)、感染(n = 9)、机械问题(n = 6)、气胸(n = 3)、上腔静脉综合征/狭窄(n = 2)和气栓(n = 1),总体并发症发生率为0.463/1000导管日。
我们得出结论,CF患者使用中心静脉留置导管相对安全。良好的感染控制措施似乎可以预防大多数感染性并发症。最常见的并发症是血栓形成,部分患者可能会复发。尽管该患者群体有严重咯血的潜在风险,但仍应考虑预防性使用华法林治疗。